Rethinking early puberty: new guidance favors watchful waiting, targeted GnRH therapy

Clinical Takeaway: Don’t reflexively order labs, imaging, or treatment for every child meeting traditional age cutoffs for central precocious puberty; assess pubertal tempo, age, symptoms, growth pattern, and likely height benefit first.

The Endocrine Society’s new clinical practice guideline on central precocious puberty (CPP) marks a shift toward more selective evaluation and treatment, particularly for older girls with slowly progressive puberty.

CPP is traditionally defined as secondary sexual characteristics before age 8 years in girls and 9 years in boys. GnRH agonists remain the first-line drug therapy for many children with confirmed CPP, especially when treatment is expected to preserve adult height or delay very early menarche. However, the guideline emphasizes that not all patients who meet age-based criteria require immediate laboratory testing, imaging, or medication.

For girls with Tanner stage B2 breast development between ages 7 and 8 years, the guideline suggests watchful waiting with physical examinations every 4 to 6 months rather than immediate labs or radiologic imaging. Girls younger than 7 years with initial Tanner B2 breast development should also generally be observed for 4 to 6 months to distinguish unsustained or slowly progressive puberty from rapidly progressive disease, unless they have Tanner B3 or higher, rapid progression, growth acceleration, or central nervous system symptoms.

When hormonal evaluation is needed, clinicians should start with an ultrasensitive basal luteinizing hormone (LH) concentration rather than routine GnRH or GnRH agonist stimulation testing for all patients. Brain MRI shouldn’t be routine in girls ages 6 to 8 years or boys ages 8 to 9 years with CPP and no CNS findings. Routine genetic testing is also discouraged, though targeted testing such as MKRN3 sequencing may be considered in familial CPP through shared decision-making.

Drug-related guidance centers on avoiding unnecessary burden. GnRH agonist therapy is suggested for many children with CPP, but older girls with slowly progressive CPP and children already at or beyond peak pubertal growth may derive less net benefit. If a long-acting GnRH agonist is planned long term, the guideline suggests starting with that formulation rather than beginning with monthly injections. Routine biochemical monitoring during GnRH agonist therapy is not recommended in clinically stable patients; use growth velocity, Tanner staging, and annual bone age assessment, reserving labs for suspected treatment failure. The guideline also suggests against routinely adding growth hormone to GnRH agonists or continuing GnRH agonist therapy beyond roughly ages 10 to 11 years in girls or 11 to 12 years in boys, unless individualized factors support continuation.

“Children who start puberty earlier than usual should be carefully evaluated so they receive the right care at the right time—without unnecessary tests or treatment,” said guideline chair Ana Claudia Latronico, MD, PhD.

Source: Latronico AC, et al. (2026, June 13). J Clin Endocrinol Metab. Central precocious puberty: an Endocrine Society clinical practice guideline